MM 111

Drug Profile

MM 111

Alternative Names: MM-111

Latest Information Update: 04 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merrimack Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Recombinant fusion proteins
  • Mechanism of Action ERBB 2 receptor antagonists; ERBB-3 receptor antagonists; Neuregulin-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Oesophageal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 26 Feb 2015 9175306 - Merrimack stops enrolment in phase II trial
  • 26 Feb 2015 Discontinued - Phase-I for Breast cancer (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV)
  • 26 Feb 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top